Scottish watchdog rejects Yervoy
May 14, 2012Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma
The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which has …
New Quad HIV pill on track for FDA approval
May 14, 2012Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad
Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group. The US regulator is …
Obesity drugs vie for approval as FDA panel backs lorcaserin
May 14, 2012Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity
An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …
BASF buys Equateq to tap into growing health ingredient business
May 11, 2012Manufacturing and Production BASF, Equateq, Phil Taylor, omega-3
BASF has said it intends to buy Equateq, a UK-based specialist in lipid ingredients that represent a ‘global growing market’, …
Outsourcing on the up, but contract manufacturing still under pressure
May 11, 2012Manufacturing and Production CMO, Jim Millar, PharmaSource, Phil Taylor, outsourcing
The pharmaceutical contract services sector experienced something for a recovery in 2011 after a lean couple of years, although the …
Code of Practice update to reflect legal changes
May 11, 2012Medical Communications ABPI, Code of Practice, MHRA, PMCPA, patient organisations
The UK pharma industry’s Code of Practice is set to be updated to bring it into line with changes in …
NICE changes its mind on Botox
May 11, 2012Sales and Marketing Allergan, Botox, NHS, NICE
NICE is now recommending Allergan’s Botox for chronic migraines, reversing its previous decision. The watchdog said in final draft guidance …
Gamification and online communities – what can pharma do?
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Facebook, Gamification, Syrum, digital marketing
Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This new …
ABPI appoints new Innovation Board Chair
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Neil Weir, Whitehead
The senior vice president of discovery at UCB, Neil Weir, has been appointed as the next Chair of the ABPI …
Teva appoints new president and chief executive
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Jeremy Levin, Teva
Ex-BMS head Dr Jeremy Levin has been appointed president and chief executive of Teva. Prior to joining Teva, Levin, who …
Patheon starts winding down Swindon operations
May 10, 2012Manufacturing and Production CMO, Patheon, Swindon, manufacturing
North American contract manufacturer Patheon is winding down some operations at its facility in Swindon, UK, with the aim of …
Pfizer’s RA drug on course for approval
May 10, 2012Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib
An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …
Novo Nordisk appoints ex-Pfizer head
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Pfizer, Robert Clark, regulatory affairs
Robert Clark will be joining Novo Nordisk as vice president, regulatory affairs. Clark will lead Novo Nordisk’s US regulatory team, …
Discount sways NICE into recommending Tarceva
May 10, 2012Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer
NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease. The watchdog said …
Lyrica fails in diabetes and HIV pain
May 9, 2012Sales and Marketing Lyrica, Pfizer, neuropathic pain, pain
Two separate Phase III trials of Lyrica have failed to show benefits in treating nerve pain – one in HIV …
Teva appoints new president of R&D
May 9, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Michael Hayden, R&D, Teva
Teva has appointed Dr Michael Hayden as its new president of global R&D and chief scientific officer at the firm’s …
GSK raises bid for Human Genome Services
May 9, 2012Research and Development, Sales and Marketing GSK, Human Genome Services, bid, takeover
The latest round in GlaxoSmithKline’s attempt to take over Human Genome Services has begun with GSK appealing directly to the …
Celgene appoints Thomas Moriarty as general counsel
May 9, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Moriarty
Celgene has appointed Thomas Moriarty as its new general counsel and corporate secretary. In this position, he will be responsible …
Pfizer releases new data for Pristiq
May 9, 2012Research and Development, Sales and Marketing Effexor, MDD, Pfizer, Pristiq, antidepressant
Pfizer has released positive data for its established antidepressant Pristiq, as it hopes to extend the use of the drug. …
The joy of segmentation
May 8, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSI, Michael Craig, marketing, segmentation
We are all different. Different heights, shapes, hair colour and we are not just different physically – what about our …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
